Aurobindo Pharma Ltd.

₹1,296.5

-15.4 (-1.2%)

AUROPHARMA Share Price

Pharmaceuticals & Biotechnology

As on March 13, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 75,277 Cr

P/E Ratio21.6

Dividend YieldN/A

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	1,289.28	Bullish
10-DMA	1,253	Bullish
20-DMA	1,214.19	Bullish
50-DMA	1,191.76	Bullish
100-DMA	1,186.31	Bullish
200-DMA	1,146.67	Bullish

Historical Performance

1 Year

18.4%

3 Years

189%

5 Years

52.8%

10 Years

77%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	3,17,237	2,90,019	2,48,554	2,34,555	2,47,746
Total Expenditure	2,51,409	2,31,589	2,11,367	1,90,710	1,94,412
Other Income	6,218	5,574	2,906	3,226	3,808
Operating Profit	72,046	64,004	40,092	47,071	57,142
Interest	4,572	2,897	1,405	486	745
Depreciation	16,494	15,217	12,446	11,265	10,554
Profit Before Tax	50,663	43,800	26,125	33,727	73,436
Consolidated Net Profit	34,859	31,730	19,275	26,482	53,348
Adjusted EPS	60	54	33	45	91

Compounded Sales Growth

10 Years:21.2

5 Years:6.6

3 Years:6.2

TTM:1.8

Compounded Profit Growth

10 Years:17.2

5 Years:4.1

3 Years:5.7

TTM:1.9

Stock Price CAGR

10 Years:5.8

5 Years:8.9

3 Years:42.2

TTM:18.4

Return on Equity

10 Years:34.6

5 Years:91.1

3 Years:32.9

last year:60

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	581	586	586	586	586
Total Reserves	3,25,952	2,97,842	2,67,813	2,45,174	2,18,713
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	11,627	18,089	8,669	9,031	8,073
Other Current Liabilities	46,233	31,610	29,799	31,065	26,843
Short Term Borrowings	53,097	40,781	42,304	21,178	48,038
Total Liabilities	4,84,920	4,38,589	3,92,125	3,36,331	3,34,013
Capital Work in Progress	32,660	27,394	44,964	29,376	24,289
Long Term Loans & Advances	9,734	7,146	7,940	5,753	6,584
Currents Investments	---	506	1,510	3,788	1,598
Short Term Loans and Advances	19,833	22,986	16,924	15,147	10,583
Total Current Assets	2,71,625	2,37,719	2,14,599	1,80,436	1,97,399
Total Assets	4,84,920	4,38,589	3,92,125	3,36,331	3,34,013
Adjusted Book Value	562	509	458	419	374

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a moderate PE of 21.6, suggesting fair valuation relative to earnings.
Over the last three years, the stock delivered a strong 3-year price CAGR of 42.2%, indicating sustained price appreciation.
The stock carries a beta of 1.0, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹72046 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹317237 million, indicating a large and established business.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 1166231.9

No. of Shares: 900 (Approx)

Performance:16.6%

P/L: ₹166231.9

NIFTY Performance: 3.4%

1 day Top Gainers